On-the-table posterior capsulotomy and 1% sodium hyaluronate.
On-the-table posterior capsulotomies were performed in 38 patients with a 30-gauge bent needle behind a bag-fixated posterior chamber J-loop lens with 10-degree angled loops. Ten of the patients (26.30%) developed fluorescein cystoid macular edema (CME) and four patients (10.52%) developed clinical CME within three months. A similar procedure was performed on 36 patients who received 1% sodium hyaluronate (Healon) between the posterior capsule and the vitreous prior to completion of the capsulotomy. One of these patients (2.78%) developed fluorescein CME within three months. In this investigation, no topical indomethacin eyedrops were used. The results seem to indicate that by maintaining a space between the posterior capsule and the anterior hyaloid membrane 1% sodium hyaluronate prevented the development of CME in a significant number of cases. This adds support to the theory that it is the anterior hyaloid membrane that protects the posterior segment of the eye.
D002387:Cataract Extraction; D004341:Drug Evaluation; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D007903:Lens Capsule, Crystalline / Q000601:surgery*; D007908:Lens, Crystalline / Q000601:surgery*; D009994:Osmolar Concentration; D014822:Vitreous Body
D006820:Hyaluronic Acid